A phase II study of clofarabine in combination with cytarabine (Ara-C) in patients [greater than or equal to] 50 years with newly diagnosed and previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) ([at least] 10% bone marrow blasts).

Trial Profile

A phase II study of clofarabine in combination with cytarabine (Ara-C) in patients [greater than or equal to] 50 years with newly diagnosed and previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) ([at least] 10% bone marrow blasts).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Clofarabine (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jan 2012 Actual initiation date (1 Feb 2006) added as reported by ClinicalTrials.gov.
    • 31 Oct 2006 Status change
    • 06 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top